MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$212,400K
(409.07%↑ Y/Y)
Proceeds from issuance of
common stock upon...
$10,136K
(70.61%↑ Y/Y)
Net cash provided by
financing activities
$222,500K
(366.81%↑ Y/Y)
Canceled cashflow
$36K
Net change in cash,
cash equivalents and...
$42,749K
(1767.58%↑ Y/Y)
Canceled cashflow
$179,751K
Payment of transaction
costs
$36K
Stock-based compensation
$26,430K
(-8.54%↓ Y/Y)
Noncash operating lease
expense
$3,961K
(5.77%↑ Y/Y)
Depreciation
$2,281K
(-8.72%↓ Y/Y)
Accrued expenses and
other liabilities
$1,104K
(-2.65%↓ Y/Y)
Sales and maturities
of marketable...
$224,640K
(-31.46%↓ Y/Y)
Net cash used in
operating activities
-$138,886K
(-5.62%↓ Y/Y)
Net cash (used in)
provided by investing...
-$40,865K
(-147.45%↓ Y/Y)
Canceled cashflow
$33,776K
Canceled cashflow
$224,640K
Net loss
-$101,594K
(22.03%↑ Y/Y)
Deferred revenue
-$62,384K
(-108.16%↓ Y/Y)
Purchases of marketable
securities
$264,457K
(9.78%↑ Y/Y)
Operating lease
liabilities
-$3,032K
(-41.68%↓ Y/Y)
Accretion on marketable
securities
-$2,688K
(41.78%↑ Y/Y)
Prepaid expenses and
other current assets
$1,763K
(576.49%↑ Y/Y)
Accounts payable
-$825K
(30.32%↑ Y/Y)
Other long-term
assets
$299K
(795.35%↑ Y/Y)
Other, net
$77K
(434.78%↑ Y/Y)
Purchase of property and
equipment
$1,048K
(38.99%↑ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
TNGX_BIG
Tango Therapeutics, Inc. (TNGX)
TNGX_BIG
Tango Therapeutics, Inc. (TNGX)